Fosun International Reports Strong 1H2026 Profit Surge on Core Business Resilience — Fosun International Limited

Event summary

Fosun International expects 1H2026 profit attributable to owners of the parent to range from RMB 1.5 billion to RMB 1.8 billion, up 127%–172% YoY.
Core industries—pharmaceuticals/healthcare, insurance/finance, and cultural tourism/consumer businesses—demonstrated strong resilience in 1H2026.
Fosun Pharma reported RMB 10.073 billion in operating revenue for Q12026 (+6.93% YoY) and RMB 871 million in net profit (+13.87% YoY).
Pramerica Fosun Life Insurance achieved RMB 786 million in net profit for 1H2026, exceeding its full-year 2025 net profit.
Yuyuan and Hainan Mining expect significant profit increases for 1H2026, with Yuyuan's net profit up 91.04%–170.64% YoY and Hainan Mining's up 68%–96% YoY.

The big picture

Fosun International's strong 1H2026 profit alert underscores the success of its strategy to exit non-core assets and focus on core industries. The significant year-over-year increases across pharmaceuticals, insurance, and consumer businesses highlight operational improvements and market resilience. This earnings recovery phase positions Fosun for potential long-term profitability, though sustained performance will depend on maintaining momentum in these key sectors.

What we're watching

Core Business Focus: How Fosun's strategy of streamlining operations and strengthening core businesses will affect long-term profitability.
Earnings Sustainability: Whether the significant profit increases in 1H2026 can be sustained through the second half of the year.
Industry Resilience: The pace at which Fosun's core industries—pharmaceuticals, insurance, and cultural tourism—continue to demonstrate resilience in a potentially volatile market.